138 related articles for article (PubMed ID: 18992277)
1. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873
[TBL] [Abstract][Full Text] [Related]
3. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
[TBL] [Abstract][Full Text] [Related]
5. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
7. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2006 Jul; 155(1):109-15. PubMed ID: 16480775
[TBL] [Abstract][Full Text] [Related]
8. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain.
Easton N; Steward C; Marshall F; Fone K; Marsden C
Neuropharmacology; 2007 Feb; 52(2):405-14. PubMed ID: 17020775
[TBL] [Abstract][Full Text] [Related]
9. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles.
LoPachin RM; Barber DS; He D; Das S
Toxicol Sci; 2006 Jan; 89(1):224-34. PubMed ID: 16207938
[TBL] [Abstract][Full Text] [Related]
10. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.
Farnsworth SJ; Volz TJ; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2009 Mar; 328(3):807-12. PubMed ID: 19038779
[TBL] [Abstract][Full Text] [Related]
11. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
Volz TJ; Hanson GR; Fleckenstein AE
Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
[TBL] [Abstract][Full Text] [Related]
13. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
14. Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.
Tucker KR; Block ER; Levitan ES
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4485-94. PubMed ID: 26216995
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
Alburges ME; Hoonakker AJ; Horner KA; Fleckenstein AE; Hanson GR
J Neurochem; 2011 May; 117(3):470-8. PubMed ID: 21323925
[TBL] [Abstract][Full Text] [Related]
17. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
[TBL] [Abstract][Full Text] [Related]
18. Alteration of dopamine uptake into rat striatal vesicles and synaptosomes caused by an in vitro exposure to atrazine and some of its metabolites.
Hossain MM; Filipov NM
Toxicology; 2008 Jun; 248(1):52-8. PubMed ID: 18423833
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.
Midde NM; Gomez AM; Zhu J
J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010
[TBL] [Abstract][Full Text] [Related]
20. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
